Armata Pharmaceuticals (ARMP) announced that it has achieved full enrollment of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Armata anticipates topline data from the diSArm study in the first quarter of 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter